Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Pizotifen→

Pizotifen Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
15574-96-6
Molecular formula
C19H21NS
Molecular weight
295.4 g/mol
Drug class
Serotonin antagonist and antihistaminemigraine prophylactic agent
Mechanism of action
Has strong antiserotonergic and antihistaminic activity, with additional antitryptaminic and weak anticholinergic effects. Its migraine-preventive action is associated with inhibition of serotonin- and histamine-mediated vascular permeability changes and related trigeminovascular signalling.
Indications / reported uses
  • Prevention of recurrent migraine attacks; it is not intended for treatment of an acute migraine attack.

Sources: https://www.medicines.org.uk/emc/product/13264/smpc · https://www.medicines.org.uk/emc/product/13265/smpc · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Pizotifen Environmental Risk Assessment (ERA) (the Pizotifen ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.